Selinexor not checked
Karyopharm Therapeutics Inc · KCP-330 · ATG-010
FollowEvery change as it happens, and a Monday email
Trials
12 active
42 in total · 12 in the EU
What this is
- How it works
- Nuclear Export Inhibitor FDA class
- How it’s given
- “Participants will receive a dose of 40 or 60 mg selinexor oral tablets QW.”In the company’s words, NCT04562389 on ClinicalTrials.gov
- Tested for
- Myelofibrosis (3 trials), Endometrial Cancer, Relapsed/Refractory Diffuse Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma, Moderate Thrombocytopenia, Mild Thrombocytopenia, Multiple Myeloma, Refractory, Multiple Myeloma
- Main trialPhase 3
- “This is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) and Phase 3 (double-blind). Phase 1 (enrollment completed) was an open-label evaluation of the safety and recommended Phase 2 dose (RP2D) of selinexor in combination with ruxolitinib and included a dose escalation using a standard 3+3 design (Phase 1a) and a dose expansion part (Phase 1b). Phase 3 (ongoing), double-blind, placebo-controlled part of…”In the company’s words, NCT04562389 on ClinicalTrials.gov
- Other names
- KCP-330 · ATG-010 · Xpovio · KPT-330
Other drugs for Myelofibrosis
- NavitoclaxAbbVie · Phase 3
- NavtemadlinKartos Therapeutics, Inc. · Phase 3
- Ropeginterferon alfa-2bPharmaEssentia · Phase 3
- ElriterceptTakeda · Phase 3
- PelabresibNovartis · Phase 3
- Imetelstat SodiumGeron Corporation · Phase 3
Coming up5
- DecPhase 2/3 trial completes · ClinicalTrials.gov
- DecPhase 2 trial completes · ClinicalTrials.gov
- Apr 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Jun 2027Phase 2 trial completes · ClinicalTrials.gov
- Jan 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials42
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 20 Feb 2026 | Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis | |
| Phase 3Active, not recruiting | 22 May 2026 | Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma | |
| Phase 2/3Active, not recruiting | Dec 2026 | A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | |
| Phase 2Active, not recruiting | Sep 2026 | A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis | |
| Phase 2Active, not recruiting | Dec 2026 | Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | |
| Phase 2Recruiting | Jun 2027 | A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia | |
| Phase 2Recruiting | Jan 2028 | A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. | |
| Phase 1/2Recruiting | Apr 2027 | Selinexor and Backbone Treatments of Multiple Myeloma Patients | |
| Phase 3Completed | 18 Feb 2020 | Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma | |
| Phase 3Completed | 22 Jan 2022 | Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO] | |
| Phase 2/3Completed | 28 Oct 2020 | Selinexor in Advanced Liposarcoma | |
| Phase 2Terminated | 10 Dec 2015 | Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas | |
| Phase 2Terminated | Jan 2016 | Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma | |
| Phase 2Terminated | 1 Apr 2016 | SHIP (Selinexor in Hormone Insensitive Prostate Cancer) | |
| Phase 2Terminated | 31 Aug 2016 | Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation | |
| Phase 2Completed | 24 Jan 2017 | Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies | |
| Phase 2Withdrawn | Jun 2017 | Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma | |
| Phase 2Withdrawn | Dec 2017 | Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients | |
| Phase 2Completed | 8 Jan 2018 | Selinexor (KPT-330) in Older Patients With Relapsed AML | |
| Phase 2Completed | 26 Jul 2019 | Selinexor Treatment of Refractory Myeloma | |
| Phase 2Terminated | 23 Jan 2020 | Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas | |
| Phase 2Withdrawn | 30 Aug 2020 | Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19 | |
| Phase 2Completed | 5 Oct 2020 | Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection | |
| Phase 2Completed | 25 Feb 2022 | A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma | |
| Phase 2Terminated | 24 Jun 2022 | A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations | |
| Phase 2Completed | 31 May 2023 | A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma | |
| Phase 2Terminated | 22 Sep 2023 | Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma | |
| Phase 1/2Withdrawn | May 2015 | Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) Patients | |
| Phase 1/2Withdrawn | Jan 2018 | Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients | |
| Phase 1/2Terminated | 3 Jul 2023 | A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma | |
| Phase 1/2Completed | 31 Jul 2024 | Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment | |
| Phase 1/2Terminated | 31 Dec 2024 | A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL | |
| Phase 1/2Withdrawn | Dec 2025 | Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) | |
| Phase 1Completed | 13 Oct 2015 | Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer | |
| Phase 1Completed | 15 Mar 2016 | Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer | |
| Phase 1Completed | 21 Oct 2016 | A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma | |
| Phase 1Terminated | 6 Feb 2023 | A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | |
| Phase 2Authorised | not given | Selinexor with alternating bortezomib or lenalidomide plus dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients (SABLe): An Investigator Sponsored Trial | |
| Phase 2Authorised | not given | Pilot phase II study of Selinexor in combination with Ifosfamide, Etoposide and Dexamethasone (SIDE) in patients with relapsed or refractory Peripheral T-cell Lymphomas | |
| Phase 1/2Not authorised | not given | Phase I/II randomized clinical trial of selinexor plus gemcitabine in selected advanced soft-tissue sarcomas | |
| Phase 3Authorised | not given | A PHASE 3 RANDOMIZED, OPEN-LABEL TRIAL OF SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPd) VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EloPd) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) | |
| Phase 1/2Authorised | not given | Phase I/II randomized clinical trial of selinexor plus gemcitabine in selected advanced soft-tissue sarcomas |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026